Showing 4151-4160 of 6036 results for "".
- Melt Pharmaceuticals Doses First Patient in Phase 3 Program of MELT-300 Opioid-Free Sedationhttps://modernod.com/news/melt-pharmaceuticals-doses-first-patient-in-pivotal-phase-3-program-of-melt-300-opioid-free-sedation/2482312/Melt Pharmaceuticals announced that the first patient has been dosed in its phase 3 program evaluating the safety and efficacy of its lead product candidate, MELT-300, a non‑IV, non-opioid tablet that combines fixed doses of midazolam (3mg) and ketamine (50mg). MELT-300 is administered sublingual
- Eversight Partners with LighTopTech to Improve Imaging Modalities for Eye Tissueshttps://modernod.com/news/eversight-partners-with-lightoptech-to-improve-imaging-modalities-for-eye-tissues/2482310/Eversight announced a 4-year partnership with LighTopTech that aims to improve imaging modalities for eye tissues in both clinical and research settings. Financial terms of the deal were not disclosed. As part of th
- Harrow Announces 52-Week Data from Vevye ESSENCE-2 Open-Label Extension Studyhttps://modernod.com/news/harrow-announces-52-week-data-from-vevye-essence-2-open-label-extension-study/2482309/Harrow has announced results from its ESSENCE‑2 open-label extension (OLE) clinical study for Vevye (cyclosporine ophthalmic solution) 0.1%, the first and only cyclosporine to treat the signs and symptoms of dry eye disease (DED). ESSENCE-2 OLE was a phase 3, prospective, multicent
- Azura Ophthalmics Enrolls First Patient in Phase 3 Clinical Trial for AZR-MD-001 in Patients with MGDhttps://modernod.com/news/azura-ophthalmics-enrolls-first-patient-in-phase-3-clinical-trial-for-azr-md-001-in-patients-with-mgd/2482307/Azura Ophthalmics announced that the first patient has been enrolled in the ASTRO study—a phase 3 clinical trial assessing the efficacy and safety of AZR-MD-001 in patients with clinical signs and symptoms of meibomian gland dysfunction (MGD). "AZR-MD-001 has already dem
- Aurion Biotech Completes Enrollment In Phase 1/2 Clinical Trial of Allogeneic Cell Therapy Candidatehttps://modernod.com/news/aurion-biotech-completes-enrollment-in-phase-12-clinical-trial-of-allogeneic-cell-therapy-candidate/2482306/Aurion Biotech announced that it has completed dosing of all subjects in its phase 1/2 clinical trial (CLARA) of AURN001, an allogeneic cell therapy for the treatment of corneal edema secondary to corneal endothelial dysfunction. “Aurion Biotech is delighted that both enrollm
- Bausch + Lomb Launches Blink NutriTears Nutritional Supplement for Dry Eyes in the UShttps://modernod.com/news/bausch-lomb-launches-blink-nutritears-nutritional-supplement-for-dry-eyes-in-the-us/2482305/Bausch + Lomb announced the US launch of Blink NutriTears, an over-the-counter supplement designed to target the key root causes of dry eyes, promote healthy tear production, and provide relief of eye dryness symptoms in as little as 2 to 4 weeks.[1,2]
- LambdaVision Closing of Seed Round to Advance Artificial Retina Preclinical Studieshttps://modernod.com/news/lambdavision-closing-of-seed-round-to-advance-artificial-retina-preclinical-studies/2482302/LambdaVision, which is developing a protein-based artificial retina to help patients regain sight lost to retinal degenerative diseases, announced it secured the first closing of its seed round. The proceeds will be used to fund LambdaVision’s GMP manufacturing scale up and critical IN
- Nordic Pharma Launches Lacrifill Canalicular Gel for Dry Eyehttps://modernod.com/news/nordic-pharma-launches-lacrifill-canalicular-gel-for-dry-eye/2482301/Nordic Pharma announced the commercial launch of Lacrifill Canalicular Gel, a novel therapy for dry eye in the US. Lacrifill is a cross-linked hyaluronic acid derivative and is FDA-cleared to temporarily block tear drainage by the occlusion of the canalicular system
- Zeiss Announces OCT Enhancements to Cirrus 6000https://modernod.com/news/zeiss-announces-oct-enhancements-to-cirrus-6000/2482299/Zeiss Medical Technology announced enhancements to the Cirrus 6000 designed to allow for a more efficient and data-driven workflow for ophthalmologists. The device is supported by the largest OCT reference database in the US market, according to Zeiss, as well a
- Quantel Medical Launches POCKET III Handheld Pachymeterhttps://modernod.com/news/quantel-medical-launches-pocket-iii-handheld-pachymeter/2482298/Quantel Medical, a division of Lumibird Medical, announced the launch of the POCKET III handheld pachymeter. With its compact design, Quantel says the POCKET III is the lightest connected handheld pachymeter on the market weighing just 60 grams. It offers a precise a